Related Experiment Video
Updated: Jul 3, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Raltegravir, an HIV-1 integrase inhibitor for HIV infection
1IrsiCaixa Foundation, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Barcelona, Spain. ccabrera@irsicaixa.es
Abstract:
Merck & Co has developed and launched raltegravir, an HIV-1 integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. This drug is the lead from a series of integrase strand transfer inhibitors and, by April 2008, it had been launched in Canada, the US, the UK, France, Germany and Spain, and had been filed for approval in Japan.
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Size and Structure of Viral Genomes
Retroviruses
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis

